Last update: Oct. 31, 2018
Minimal risk for breastfeeding and infant.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension, heart failure, myocardial infarction and type 1 diabetic nephropathy.
Oral administration every 8-12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, FT 2018, Serrano 2015, Drummer 1986, Devlin 1981) and no problems have been observed in infants whose mothers were taking it (Anderson 2018, Devlin 1981).
Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in mothers of premature infants (Serrano 2015).
There are conflicting reports about the effect of captopril on the secretion of prolactin (Saito 1990, Denolle 1990, Anderson 1989). However, when breastfeeding is well established, milk production does not depend on prolactin levels.
Expert authors and medical associations such as the American Academy of Pediatrics consider it to be usually compatible with breastfeeding (Serrano 2015, Rowe 2013, Dennis 2012, Ghanem 2008, AAP 2001, Kirsten 1998).
List of essential medicines WHO: compatible with breastfeeding (WHO/UNICEF, 2002).
We do not have alternatives for Captopril since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2021 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM